MCM
TLSI icon

MAI Capital Management’s TriSalus Life Sciences TLSI Stock Holding History

MAI Capital Management’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15
Closed -$60 – 4484
2026
Q1 		$60 Buy
+15
New +$73 ﹤0.01% 4841

Other funds holding TLSI

FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Cerity Partners
Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WPC
White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return

MAI Capital Management's TLSI Position: Q2 2026 in Review

MAI Capital Management sold out of TriSalus Life Sciences (TLSI) in Q2 2026, closing a stake of 15 shares — an estimated $60 sold.

MAI Capital Management first reported a position in TLSI in Q1 2026 and held it in 1 quarter. The position peaked at $60 in Q1 2026. 78 funds tracked by Wall St. Rank hold TLSI as of Q2 2026.

  • MAI Capital Management reported no remaining TriSalus Life Sciences position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 15 TriSalus Life Sciences shares in Q2 2026, an estimated $60.
  • MAI Capital Management first reported a position in TriSalus Life Sciences in Q1 2026 and held it in 1 quarter.
  • MAI Capital Management's TriSalus Life Sciences position peaked at $60 in Q1 2026.
  • 78 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.